Fibromyalgia Treatments Market Research Report- Global Forecast To 2023

Fibromyalgia Treatments Market Research Report- Global Forecast To 2023

ID: MRFR/HC/1347-HCRR | April, 2018 | Region: Global | 85 pages | Half-Cooked Research Reports

Fibromyalgia Treatment Market Research Report: By treatment (targeted (antidepressant, anti-seizure drug), symptomatic treatment, diagnosis (laboratory evaluation, presence of central sensitization), end user (hospital &clinic) - forecast till 2022 


Market Scenario


Fibromyalgia is a condition that causes lasting and debilitating muscle pain and fatigue. In the recent years, cases of road traffic injuries have been rising at an alarming rate, which further leads to the rising prevalence of fibromyalgia as road traffic accidents are likely to develop widespread chronic pain. Psychiatric disorders are increasingly prevalent in case of fibromyalgia, and post-traumatic stress disorders are also seen with the increasing occurrence rate. Screening for post-traumatic stress disorder symptoms is also an essential part of the assessment process in patients suffering from fibromyalgia.


It is noted that the rising occurrences of traumatic stress and road accidents is the key factor driving the fibromyalgia treatment market. According to a study published in the Pain Research and Management Journal, in 2014, it was found that physical trauma is followed by the fibromyalgia syndrome. In the study, conducted with a specific cohort of individuals involved in motor vehicle collisions, it was found that 8% of individuals developed widespread chronic pain. Fibromyalgia is characterized by widespread chronic pain. The study has also demonstrated the incidence rate of fibromyalgia in the survivors of a train crash in Israel which was 15%.


Other factors, such as increasing cases of rheumatic diseases, growing awareness among the population, rising geriatric population, unmet medical needs in the fibromyalgia treatment, and rising popularity of Chinese treatment options are also promoting the growth of the market. Fibromyalgia is considered as a confounding factor for the diagnosis and the assessment of the rheumatic disease activity.


Despite these drivers, there are some issues associated with the fibromyalgia treatment market. Lack of infrastructure in middle- and low-income countries and difficult diagnosis may hamper the growth of the market. Irritable Bowel Syndrome (IBS) is also found to be highly associated with fibromyalgia. According to the study published in the Medicine Journal in 2015, fibromyalgia was associated with a 1.54-fold increased risk for the irritable bowel syndrome. In Taiwan, the incidence rate of IBS is found to be around 10 to 20%, whereas the incidence rate of fibromyalgia in Taiwan's general population is around 2 to 4%.


It is estimated that the Fibromyalgia Treatment Market Is Expected To Grow at a CAGR Of 17.5% During The Forecast Period Of 2017 To 2023.


Research Methodology


 Fibromyalgia Treatment Market


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Hospitals

  • Diagnostic Clinics

  • Drug Stores

  • Research and Development (R&D) Companies

  • Government Research Institutes

  • Academic Institutes and Universities


Segmentation


The fibromyalgia treatment market is segmented on the basis of treatment, diagnosis, and end-user.


On the basis of treatment, the market is segmented into symptomatic treatment and targeted treatment.


On the basis of diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.


On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others.


Regional Analysis


The Americas dominates the fibromyalgia treatment market owing to the rising awareness among people, rising cases of chronic rheumatic diseases, and increasing healthcare expenditure. As per the 2017 statistics suggested by the Centers for Disease Control and Prevention (CDC), around 54.4 million adults in the United States have arthritis, which is about 25% of the population. It is also reported that by 2040, nearly 78 million adults, aged 18 years or older, are projected to have arthritis in the United States.


Europe holds the second position in the fibromyalgia treatment market. It is expected that the financial support provided by governments and private bodies for research and development and amendments in reimbursement policies in healthcare will drive the fibromyalgia treatment market in Europe.


Asia Pacific is the fastest growing market for fibromyalgia treatments, owing to a huge patient pool and rising healthcare expenditure in some countries within this region. In 2014, the total expenditure on healthcare per capita was USD 731 in China, suggested by the World Health Organization (WHO). According to the BMC Health Services Research Journal, China’s healthcare expenditure grew at a rate of 11.6% per year. The rate is much faster than the growth of the country’s economy, i.e., 9.9% per year.


The Middle East and Africa has the lowest market for fibromyalgia treatments due to lack of technical knowledge and poor medical facilities.


Key Players


Some of the key players in the fibromyalgia treatment market are Pfizer, GlaxoSmithKline, AstraZeneca, F. Hoffmann-La Roche AG, Astellas Pharma, Johnson & Johnson Services, Inc., SANOFI, Eli Lilly and Company, Bayer AG, ALLERGAN, Boehringer Ingelheim, AbbVie, Cephalon, Inc., Sunovion Pharms Inc, Jazz Pharmaceuticals, Vertical Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Fibromyalgia Treatment Market, by Diagnosis

6.1 Introduction

6.2 Laboratory Evaluation

6.2.1 Market Estimates & Forecast, 2017–2023

6.3 Presence of Central Sensitization

6.3.1 Market Estimates & Forecast, 2017–2023

Chapter 7. Global Fibromyalgia Treatment Market, by Treatment

7.1 Introduction

7.2 Symptomatic Treatment

7.2.1 Market Estimates & Forecast, 2017–2023

7.3 Targeted Treatment

7.3.1 Market Estimates & Forecast, 2017–2023





Chapter 8. Global Fibromyalgia Treatment Market, by End-User

8.1 Introduction

8.2 Hospital

8.2.1 Market Estimates & Forecast, 2017–2023

8.3 Clinics

8.3.2 Market Estimates & Forecast, 2017–2023

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2017–2023

8.5 Others

8.5.2 Market Estimates & Forecast, 2017–2023

Chapter 9. Global Fibromyalgia Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Pfizer

11.1.1 Company Overview

11.1.2 Types Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 GlaxoSmithKline

11.2.1 Company Overview

11.2.2 Types Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 AstraZeneca

11.3.1 Company Overview

11.3.2 Types Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 F. Hoffmann-La Roche AG

11.4.1 Company Overview

11.4.2 Types/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Astellas Pharma

11.5.1 Company Overview

11.5.2 Types Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Johnson & Johnson Services, Inc.

11.6.1 Company Overview

11.6.2 Types Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 SANOFI

11.7.1 Overview

11.7.2 Types Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Fibromyalgia Treatment industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Fibromyalgia Treatment Industry Synopsis, 2017–2023

Table 2 Fibromyalgia Treatment Market Estimates and Forecast, 2017–2023, (USD Million)

Table 3 Fibromyalgia Treatment Market, by Region, 2017–2023, (USD Million)

Table 4 Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 5 Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 6 Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 7 North America Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 8 North America Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 9 North America Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 10 US Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 11 US Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 12 US Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 13 Canada Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 14 Canada Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 15 Canada Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 16 South America Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 17 South America Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 18 South America Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 19 Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 20 Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 21 Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 22 Western Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 23 Western Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 24 Western Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 25 Eastern Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 26 Eastern Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 27 Eastern Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 28 Asia Pacific Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 29 Asia Pacific Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 30 Asia Pacific Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

Table 31 Middle East & Africa Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)

Table 32 Middle East & Africa Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)

Table 33 Middle East & Africa Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Fibromyalgia Treatment Market

Figure 3 Segmentation Market Dynamics for Fibromyalgia Treatment Market

Figure 4 Global Fibromyalgia Treatment Market Share, by Diagnosis, 2016

Figure 5 Global Fibromyalgia Treatment Market Share, by Treatment, 2016

Figure 6 Global Fibromyalgia Treatment Market Share, by End-User, 2016

Figure 7 Global Fibromyalgia Treatment Market Share, by Region, 2016

Figure 8 North America Fibromyalgia Treatment Market Share, by Country, 2016

Figure 9 Europe Fibromyalgia Treatment Market Share, by Country, 2016

Figure 10 Asia Pacific Fibromyalgia Treatment Market Share, by Country, 2016

Figure 11 Middle East & Africa Fibromyalgia Treatment Market Share, by Country, 2016

Figure 12 Global Fibromyalgia Treatment Market: Company Share Analysis, 2016 (%)

Figure 13 Pfizer: Key Financials

Figure 14 Pfizer Segmental Revenue

Figure 15 Pfizer: Geographical Revenue

Figure 16 GlaxoSmithKline: Key Financials

Figure 17 GlaxoSmithKline: Segmental Revenue

Figure 18 GlaxoSmithKline: Geographical Revenue

Figure 19 AstraZeneca: Key Financials

Figure 20 AstraZeneca: Segmental Revenue

Figure 21 AstraZeneca: Geographical Revenue

Figure 22 F. Hoffmann-La Roche AG: Key Financials

Figure 23 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 24 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 25 Astellas Pharma: Key Financials

Figure 26 Astellas Pharma: Segmental Revenue

Figure 27 Astellas Pharma Geographical Revenue

Figure 28 Johnson & Johnson Services, Inc.: Key Financials

Figure 29 Johnson & Johnson Services, Inc.: Segmental Revenue

Figure 30 Johnson & Johnson Services, Inc.: Geographical Revenue

Figure 31 SANOFI: Key Financials

Figure 32 SANOFI: Segmental Revenue

Figure 33 SANOFI: Geographical Revenue